Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27713597 | 0.88 | HDAC1 (0.53) | RENMEN1KMT2ATDP1TSHR | |
| SCHEMBL13723052 | 0.86 | REN (0.50) | RENMEN1KMT2ALMNATDP1 | |
| SCHEMBL23120893 | 0.86 | MEN1 (0.53) | MEN1KMT2ALMNATDP1MAPT | |
| SCHEMBL23120176 | 0.85 | ALOX5 (0.56) | — | |
| SCHEMBL23120140 | 0.85 | MC4R (0.50) | — | |
| SCHEMBL23121020 | 0.84 | ALOX5 (0.49) | RENMEN1KMT2ATDP1MAPT | |
| SCHEMBL23120179 | 0.84 | PTGES (0.58) | TSHR | |
| SCHEMBL7172779 | 0.84 | TDP1 (0.45) | RENMEN1KMT2ALMNATDP1 | |
| SCHEMBL27713598 | 0.82 | CCR6 (0.52) | RENMEN1KMT2ALMNATDP1 | |
| SCHEMBL23120348 | 0.82 | PTGES (0.59) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024109929-A1 | IONIZABLE LIPID AND USE THEREOF | 艾斯拓康医药科技(北京)有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2579887-B1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | SEATTLE GENETICS INC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2790731-A2 | FGFR-BINDER-ACTIVE AGENT CONJUGATES | Seattle Genetics, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| EP-2699268-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | Seattle Genetics, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2013087716-A2 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| EP-2579887-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | Seattle Genetics, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012143499-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143497-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | INCYTE CORPORATION (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2011154359-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | disclosed |
| US-8039478-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2005118613-A2 | ANTIBACTERIAL AMIDE MACROCYCLES | AICURIS GMBH & CO.KG (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005033129-A1 | ANTIBACTERIAL AMIDE MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | GPR84, P2RY1, ADRA1A | REN 1348/4885MEN1 1825/4885KMT2A 1601/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | REN 678/4885MEN1 2520/4885KMT2A 2660/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | REN 678/4885MEN1 2520/4885KMT2A 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.